These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31987911)

  • 1. Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome.
    Tramutola A; Lanzillotta C; Di Domenico F; Head E; Butterfield DA; Perluigi M; Barone E
    Neurobiol Dis; 2020 Apr; 137():104772. PubMed ID: 31987911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome.
    Lanzillotta C; Tramutola A; Di Giacomo G; Marini F; Butterfield DA; Di Domenico F; Perluigi M; Barone E
    Free Radic Biol Med; 2021 Mar; 165():152-170. PubMed ID: 33516914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain insulin resistance in Down syndrome: Involvement of PI3K-Akt/mTOR axis in early-onset of Alzheimer's disease and its potential as a therapeutic target.
    Azimzadeh M; Cheah PS; Ling KH
    Biochem Biophys Res Commun; 2024 Nov; 733():150713. PubMed ID: 39307112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.
    Perluigi M; Pupo G; Tramutola A; Cini C; Coccia R; Barone E; Head E; Butterfield DA; Di Domenico F
    Biochim Biophys Acta; 2014 Jul; 1842(7):1144-53. PubMed ID: 24735980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.
    Tramutola A; Di Domenico F; Barone E; Arena A; Giorgi A; di Francesco L; Schininà ME; Coccia R; Head E; Butterfield DA; Perluigi M
    Antioxid Redox Signal; 2017 Mar; 26(7):280-298. PubMed ID: 27627691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.
    Martínez-Cué C; Rueda N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease.
    Coskun P; Helguera P; Nemati Z; Bohannan RC; Thomas J; Samuel SE; Argueta J; Doran E; Wallace DC; Lott IT; Busciglio J
    J Alzheimers Dis; 2017; 55(2):737-748. PubMed ID: 27802222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.
    Di Domenico F; Pupo G; Tramutola A; Giorgi A; Schininà ME; Coccia R; Head E; Butterfield DA; Perluigi M
    Free Radic Biol Med; 2014 Jun; 71():270-280. PubMed ID: 24675226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.
    Cenini G; Fiorini A; Sultana R; Perluigi M; Cai J; Klein JB; Head E; Butterfield DA
    Free Radic Biol Med; 2014 Nov; 76():89-95. PubMed ID: 25151119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterising the brain metalloproteome in Down syndrome patients with concomitant Alzheimer's pathology.
    Malakooti N; Roberts B; Pritchard MA; Volitakis I; Kim RC; Lott IT; McLean CA; Finkelstein DI; Adlard PA
    Metallomics; 2020 Jan; 12(1):114-132. PubMed ID: 31764918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.
    Martin SB; Dowling AL; Lianekhammy J; Lott IT; Doran E; Murphy MP; Beckett TL; Schmitt FA; Head E
    J Alzheimers Dis; 2014; 42(3):767-75. PubMed ID: 24927707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Medial Septum Is Insulin Resistant in the AD Presymptomatic Phase: Rescue by Nerve Growth Factor-Driven IRS
    Sposato V; Canu N; Fico E; Fusco S; Bolasco G; Ciotti MT; Spinelli M; Mercanti D; Grassi C; Triaca V; Calissano P
    Mol Neurobiol; 2019 Jan; 56(1):535-552. PubMed ID: 29736736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology.
    Seidl R; Cairns N; Singewald N; Kaehler ST; Lubec G
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):139-45. PubMed ID: 11218066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative Stress Kinase Activation and Impaired Insulin Receptor Signaling Precede Overt Alzheimer's Disease Neuropathology.
    Shen WB; Elahi M; Wang B; Zhan M; Yang P; Yang P
    J Alzheimers Dis; 2022; 90(2):841-857. PubMed ID: 36189587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.
    Tramutola A; Pupo G; Di Domenico F; Barone E; Arena A; Lanzillotta C; Brokeaart D; Blarzino C; Head E; Butterfield DA; Perluigi M
    J Alzheimers Dis; 2016; 52(1):359-371. PubMed ID: 26967221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.
    Wegiel J; Flory M; Kuchna I; Nowicki K; Wegiel J; Ma SY; Zhong N; Bobrowicz TW; de Leon M; Lai F; Silverman WP; Wisniewski T
    Acta Neuropathol Commun; 2022 Jan; 10(1):2. PubMed ID: 34983655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles.
    Perluigi M; Picca A; Montanari E; Calvani R; Marini F; Matassa R; Tramutola A; Villani A; Familiari G; Domenico FD; Butterfield DA; Oh KJ; Marzetti E; Valentini D; Barone E
    Alzheimers Dement; 2022 Aug; 18(8):1498-1510. PubMed ID: 34812584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.
    Arena A; Iyer AM; Milenkovic I; Kovacs GG; Ferrer I; Perluigi M; Aronica E
    Curr Alzheimer Res; 2017; 14(12):1305-1317. PubMed ID: 28720071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant protein expression of transcription factors BACH1 and ERG, both encoded on chromosome 21, in brains of patients with Down syndrome and Alzheimer's disease.
    Shim KS; Ferrando-Miguel R; Lubec G
    J Neural Transm Suppl; 2003; (67):39-49. PubMed ID: 15068237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.
    Wilcock DM; Hurban J; Helman AM; Sudduth TL; McCarty KL; Beckett TL; Ferrell JC; Murphy MP; Abner EL; Schmitt FA; Head E
    Neurobiol Aging; 2015 Sep; 36(9):2468-74. PubMed ID: 26103884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.